Femasys Regains Nasdaq Compliance Following Reverse Stock Split
FEMY is trading near its 52-week low of $3.77 (10% above the low) on light trading volume (0.2× avg).
Summary
Femasys has successfully regained compliance with Nasdaq listing requirements, resolving a major risk factor. This positive development follows the company's 1-for-20 reverse stock split, which became effective on June 5, 2026. The reverse split was specifically implemented to address the previously disclosed risk of Nasdaq delisting and concerns about the company's ability to continue as a going concern, as highlighted in its March 31, 2026 10-K filing. Removing the delisting threat is crucial for the company's market access and investor confidence.
At the time of this announcement, FEMY was trading at $4.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1M. The 52-week trading range was $3.77 to $22.20. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.